Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Shangha Pan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2190-2084; OpenAlex author ID A5000244296. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: none · 2014: 2 papers · 2015: none · 2016: 3 papers · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 17

  1. Correction: UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1. Co-author DOI 10.1186/s13046-026-03696-5↗
  2. circEIF3I facilitates the recruitment of SMAD3 to early endosomes to promote TGF-β signalling pathway-mediated activation of MMPs in pancreatic cancer. Co-author DOI 10.1186/s12943-023-01847-2↗
  3. Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer. Last author DOI 10.1111/cas.15388↗
  4. A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growth and Metastasis. Co-author DOI 10.1158/1078-0432.ccr-18-4113↗
  5. Overexpression of KLF5 is associated with poor survival and G1/S progression in pancreatic cancer. Co-author DOI 10.18632/aging.102096↗
  6. Crucial microRNAs and genes in metformin's anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis. Co-author DOI 10.1007/s10637-017-0508-2↗
  7. Silencing IGFBP-2 decreases pancreatic cancer metastasis and enhances chemotherapeutic sensitivity. Co-author DOI 10.18632/oncotarget.18669↗
  8. Hyperoside induces apoptosis and inhibits growth in pancreatic cancer via Bcl-2 family and NF-κB signaling pathway both in vitro and in vivo. Co-author DOI 10.1007/s13277-015-4552-2↗
  9. Dihydroartemisinin suppresses pancreatic cancer cells via a microRNA-mRNA regulatory network. Co-author DOI 10.18632/oncotarget.11517↗
  10. Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer. Co-author DOI 10.18632/oncotarget.12365↗
  11. Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway. Co-author DOI 10.1016/j.bcp.2014.01.041↗
  12. The activation of c-Jun NH₂-terminal kinase is required for dihydroartemisinin-induced autophagy in pancreatic cancer cells. Co-author DOI 10.1186/1756-9966-33-8↗
  13. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both… Co-author DOI 10.1007/s00432-012-1152-z↗
  14. Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5. Co-author DOI 10.1371/journal.pone.0037222↗
  15. Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0043826↗
  16. Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway. Co-author DOI 10.1007/s00280-011-1643-7↗
  17. Nuclear factor-κB-dependent epithelial to mesenchymal transition induced by HIF-1α activation in pancreatic cancer cells under hypoxic conditions. Co-author DOI 10.1371/journal.pone.0023752↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rui Kong · 12 shared papers, 2011–2023 · strength 0.81
  2. Bei Sun · 14 shared papers, 2011–2022 · strength 0.77
  3. Yongwei Wang · 10 shared papers, 2011–2023 · strength 0.65
  4. Chundong Cheng · 3 shared papers, 2022–2026 · strength 0.54
  5. Yilong Li · 7 shared papers, 2014–2022 · strength 0.53
  6. Le Li · 4 shared papers, 2018–2023 · strength 0.44
  7. Jisheng Hu · 4 shared papers, 2017–2023 · strength 0.42
  8. Hongze Chen · 4 shared papers, 2016–2023 · strength 0.41
  9. Zhongjie Zhao · 4 shared papers, 2016–2023 · strength 0.41
  10. Le Li · 2 shared papers, 2016–2026 · strength 0.32
  11. Hongze Chen · 1 shared paper, 2026 · strength 0.27
  12. Bei Sun · 1 shared paper, 2026 · strength 0.27
  13. Danxi Liu · 2 shared papers, 2022–2023 · strength 0.27
  14. Zengfu Song · 2 shared papers, 2014–2023 · strength 0.18
  15. Guang Jia · 5 shared papers, 2011–2014 · strength 0.16
  16. Yongwei Wang · 2 shared papers, 2014–2022 · strength 0.16
  17. Xinglong Geng · 1 shared paper, 2023 · strength 0.14
  18. Yan Luo · 1 shared paper, 2023 · strength 0.14
  19. Guanqun Li · 1 shared paper, 2023 · strength 0.14
  20. Wenbo Yang · 1 shared paper, 2023 · strength 0.14
  21. Yangyang Zhang · 1 shared paper, 2023 · strength 0.14
  22. Bei Sun · 1 shared paper, 2023 · strength 0.14
  23. Hongchi Jiang · 5 shared papers, 2011–2014 · strength 0.14
  24. Gang Wang · 2 shared papers, 2016–2019 · strength 0.14
  25. Gang Wang · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.